NRG-HN011

Open to Accrual

Return to Protocol Table

A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Principal Investigator

Brigette Ma, MD,

Status

Open to Accrual

Date Opened To Accrual

January 08 2024

Disease Site

Head and Neck [HN]

Head and Neck

Phase

Developmental Therapeutics

Primary Objective

To determine if adding BMS-986016 (relatlimab) to nivolumabmaintenance therapy shows a signal of improved progression-free survival (PFS)according to RECIST 1.1 in patients who do not progress following treatmentwith platinum-gemcitabine-nivolumab combination in the first-line treatment ofrecurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC).

Patient Population

Pathologically (histologically or cytologically) provendiagnosis of nasopharyngeal carcinoma (NPC) that has recurred locoregionallyand/or is present at distant sites.

Target Accrual

156

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.